[go: up one dir, main page]

WO2004080389A3 - Hydroxyeicosadienamide compounds - Google Patents

Hydroxyeicosadienamide compounds Download PDF

Info

Publication number
WO2004080389A3
WO2004080389A3 PCT/US2004/005222 US2004005222W WO2004080389A3 WO 2004080389 A3 WO2004080389 A3 WO 2004080389A3 US 2004005222 W US2004005222 W US 2004005222W WO 2004080389 A3 WO2004080389 A3 WO 2004080389A3
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
hydroxyeicosadienamide
compounds
aryl group
substituted aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/005222
Other languages
French (fr)
Other versions
WO2004080389A2 (en
Inventor
John R Falck
Tohru Tanami
Naoya Ono
Tomomichi Chonan
Hitomi Hirano
Noriyuki Miyata
Yoshihisa Toda
Shigeru Okuyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
University of Texas System
University of Texas at Austin
Original Assignee
Taisho Pharmaceutical Co Ltd
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd, University of Texas System, University of Texas at Austin filed Critical Taisho Pharmaceutical Co Ltd
Publication of WO2004080389A2 publication Critical patent/WO2004080389A2/en
Publication of WO2004080389A3 publication Critical patent/WO2004080389A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a hydroxyeicosadienamide compound an excellent inhibitory effect on elastase release, which is represented by Formula (I): (I), wherein n represents an integer of 0 to 5, and R represents an optionally substituted C1-20 alkyl group, an optionally substituted aryl group, -NRXRY, an optionally substituted unsaturated heterocyclic ring, or -(C1-4 alkylene)-Q or Q, wherein Q is an optionally substituted C4-10 bridged hydrocarbon or an optionally substituted aryl group, or a pharmaceutically acceptable salt or hydrate thereof.
PCT/US2004/005222 2003-03-07 2004-03-05 Hydroxyeicosadienamide compounds Ceased WO2004080389A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45256203P 2003-03-07 2003-03-07
US60/452,562 2003-03-07

Publications (2)

Publication Number Publication Date
WO2004080389A2 WO2004080389A2 (en) 2004-09-23
WO2004080389A3 true WO2004080389A3 (en) 2004-12-09

Family

ID=32990663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/005222 Ceased WO2004080389A2 (en) 2003-03-07 2004-03-05 Hydroxyeicosadienamide compounds

Country Status (1)

Country Link
WO (1) WO2004080389A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2208720A1 (en) 2009-01-13 2010-07-21 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Novel eicosanoid derivatives
MX368689B (en) * 2014-01-22 2019-10-11 Max Delbrueck Centrum Fuer Molekulare Medizin Novel cyp-eicosanoid derivatives.
WO2017156164A1 (en) 2016-03-09 2017-09-14 Board Of Regents, The University Of Texas System 20-hete receptor (gpr75) antagonists and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6359158B1 (en) * 1998-05-15 2002-03-19 University Of Vermont And State Agricultural College Methods and products related to 16-HETE analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6359158B1 (en) * 1998-05-15 2002-03-19 University Of Vermont And State Agricultural College Methods and products related to 16-HETE analogs

Also Published As

Publication number Publication date
WO2004080389A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2005061458A3 (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EP3284519A8 (en) Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
WO2008108380A3 (en) Pyrrole compounds
IL177537A (en) Viral polymerase inhibitors and pharmaceutical compositions comprising them
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
WO2008114819A1 (en) Novel adenine compound
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
MA30636B1 (en) PROMEDICING OF A CINNAMIDE COMPOUND
WO2008108386A1 (en) Pharmaceutical composition
EP1591446A4 (en) THIENOPYRIMIDINE COMPOUNDS AND USE
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
MEP61208A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
NO20053246L (en) Condensed 1,3-dihydroimidazole ring compound.
WO2004083174A3 (en) Sulfonyl-amidino containing and tetrahydropyrimidino containing compounds as factor xa inhibitors
MX2009006907A (en) Glucokinase-activating substance.
WO2005061450A3 (en) Hiv protease inhibiting sulfonamides
ATE429429T1 (en) PHARMACEUTICAL PROCESS AND COMPOUNDS PRODUCED THEREFROM
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
WO2006135828A3 (en) Trisubstituted amines as phosphodiesterase 4 inhibitors
WO2008136378A1 (en) Novel sulfonamide derivative and salt thereof
WO2005058841A3 (en) Hiv protease inhibiting compounds
WO2004080389A3 (en) Hydroxyeicosadienamide compounds
PL1692098T3 (en) Alpha-ketoamide derivative, and production method and use thereof
ATE504583T1 (en) 4-IMIDAZOLINE-2-ONE COMPOUNDS
NO20063111L (en) Process for the preparation of thiazole pyrimidines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase